GlassScriptPhysician profile
Alexander Hacopian
NPI 1487009866
$12,820.76
in general payments reported to CMS, 2019-2025
27 companies · $2,215 in 2025
The $2,215 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $187 · 2021: $3,449 · 2022: $2,318 · 2023: $1,998 · 2024: $2,655 · 2025: $2,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,867.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $3,049.98 | 2020-2024 | Idose |
| Alcon Vision LLC | $2,791.65 | 2020-2025 | Hydrus Microstent, Clareon, Unity |
| Abbvie INC. | $1,541.93 | 2022-2025 | |
| Allergan, INC. | $1,015.96 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $690.14 | 2021-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $611.94 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $518.33 | 2022-2025 | Cequa |
| New World Medical,INC. | $406.09 | 2022-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Oyster Point Pharma, INC. | $239.15 | 2022-2024 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec Cataract Technology INC. | $214.36 | 2024 | |
| Bausch & Lomb Americas INC. | $210.88 | 2022-2025 | Xiidra, Envista Mx60 Iol, Prolensa |
| Carl Zeiss Meditec USA, INC. | $177.49 | 2024 | |
| Biotissue Holdings INC. | $172.10 | 2024 | |
| Aerie Pharmaceuticals, INC. | $164.80 | 2020-2021 | |
| Dompe US, INC. | $150.46 | 2024 | Oxervate |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $149.67 | 2024 | Tepezza |
| Sight Sciences, INC. | $138.18 | 2021-2024 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $133.76 | 2023-2025 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.32 | 2020-2021 | |
| Optos, INC. | $92.73 | 2021 | |
| Thea Pharma INC. | $67.37 | 2023-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $61.29 | 2022-2023 | |
| Harrow Eye, LLC | $50.82 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $23.70 | 2021 | |
| Astellas Pharma US INC | $23.11 | 2024 | Izervay |
| Eyepoint US, INC. | $18.55 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Hacopian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.